Contribution of Dolutegravir to Obesity and Cardiovascular Disease
Status:
Recruiting
Trial end date:
2022-01-30
Target enrollment:
Participant gender:
Summary
The goal of the study is to combine a collaborative and translational approach to evaluate
the effect antiretroviral regimen switch to a dolutegravir containing regimen compared to
continued treatment with a non- dolutegravir based regimen on on lipid and metabolic
profiles, renal function, body composition, vascular function and diet.